Catching Up on Schizophrenia Natural History and Neurobiology

[1]  Pat Levitt,et al.  Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex , 2000, Neuron.

[2]  M. Laruelle,et al.  Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.

[3]  J. Lieberman,et al.  Cortical Bcl-2 protein expression and apoptotic regulation in schizophrenia , 2000, Biological Psychiatry.

[4]  E G Jones,et al.  Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  David A. Lewis,et al.  Is There a Neuropathology of Schizophrenia? Recent Findings Converge on Altered Thalamic-Prefrontal Cortical Connectivity , 2000 .

[6]  D. German,et al.  Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia , 2000, Biological Psychiatry.

[7]  W. Honer,et al.  Location of a major susceptibility locus for familial schizophrenia on chromosome 1q21-q22. , 2000, Science.

[8]  Yogesh K. Dwivedi,et al.  223. Reelin and GAD67 downregulation and psychosis vulnerability , 2000, Biological Psychiatry.

[9]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[10]  Marc Laruelle,et al.  The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies , 2000, Brain Research Reviews.

[11]  A. Sampson,et al.  Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. , 2000, Archives of general psychiatry.

[12]  M. Tsuang.  Schizophrenia: genes and environment , 2000, Biological Psychiatry.

[13]  A. Pulver.  Search for schizophrenia susceptibility genes , 2000, Biological Psychiatry.

[14]  J A Frank,et al.  Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. , 2000, The American journal of psychiatry.

[15]  D. Lewis,et al.  Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. , 2000, Archives of general psychiatry.

[16]  J. Pierri,et al.  Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. , 1999, The American journal of psychiatry.

[17]  E. Bromet,et al.  Epidemiology and natural history of schizophrenia , 1999, Biological Psychiatry.

[18]  A. Sampson,et al.  Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. , 1999, The American journal of psychiatry.

[19]  Jeffrey A Lieberman,et al.  Is schizophrenia a neurodegenerative disorder? a clinical and neurobiological perspective , 1999, Biological Psychiatry.

[20]  A Reichenberg,et al.  Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. , 1999, The American journal of psychiatry.

[21]  Marc G Caron,et al.  Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.

[22]  W. Honer,et al.  Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness , 1999, Neuroscience.

[23]  M. Laruelle,et al.  Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.

[24]  J. Rapoport,et al.  Progressive cortical change during adolescence in childhood-onset schizophrenia. A longitudinal magnetic resonance imaging study. , 1999, Archives of general psychiatry.

[25]  N. Makris,et al.  Cortical abnormalities in schizophrenia identified by structural magnetic resonance imaging. , 1999, Archives of general psychiatry.

[26]  R. McCarley,et al.  MRI anatomy of schizophrenia , 1999, Biological Psychiatry.

[27]  J. Lieberman,et al.  Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. , 1999, The American journal of psychiatry.

[28]  Paul J. Harrison.  The neuropathology of schizophrenia , 2008 .

[29]  R. Roth,et al.  The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia , 1999, Neuropsychopharmacology.

[30]  J. Lieberman,et al.  Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.

[31]  P. Andersen,et al.  Effects of family history and place and season of birth on the risk of schizophrenia. , 1999, The New England journal of medicine.

[32]  D. Weinberger,et al.  Cell biology of the hippocampal formation in schizophrenia , 1999, Biological Psychiatry.

[33]  P. Goldman-Rakic,et al.  The reduced neuropil hypothesis: a circuit based model of schizophrenia , 1999, Biological Psychiatry.

[34]  Philip D. Harvey,et al.  Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients , 1999, Biological Psychiatry.

[35]  W Q Sturner,et al.  Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for ‘hypofrontality’ , 1999, Molecular Psychiatry.

[36]  R. Gur,et al.  Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. , 1998, The American journal of psychiatry.

[37]  J A Frank,et al.  Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. , 1998, The American journal of psychiatry.

[38]  S. Hirsch,et al.  Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia , 1998, Journal of neurology, neurosurgery, and psychiatry.

[39]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[40]  Lina Shihabuddin,et al.  Ventricular Enlargement in Poor-Outcome Schizophrenia , 1998, Biological Psychiatry.

[41]  A. Malhotra,et al.  Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach , 1998, Synapse.

[42]  N. Alpert,et al.  Impaired recruitment of the hippocampus during conscious recollection in schizophrenia , 1998, Nature Neuroscience.

[43]  Ron Kikinis,et al.  Volumetric Evaluation of the Thalamus in Schizophrenic Male Patients Using Magnetic Resonance Imaging , 1998, Biological Psychiatry.

[44]  P. Goldman-Rakic,et al.  Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. , 1998, Archives of general psychiatry.

[45]  P. Sham,et al.  Obstetric complications and familial morbid risk of psychiatric disorders. , 1998, American journal of medical genetics.

[46]  D. Weinberger,et al.  Schizophrenia as a developmental disorder of the cerebral cortex , 1998, Current Opinion in Neurobiology.

[47]  Tyrone D. Cannon,et al.  A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. , 1998, Archives of general psychiatry.

[48]  A. Riecher-Rössler,et al.  Causes and consequences of the gender difference in age at onset of schizophrenia. , 1998, Schizophrenia bulletin.

[49]  R. Yolken,et al.  Seasonality of births in schizophrenia and bipolar disorder: a review of the literature , 1997, Schizophrenia Research.

[50]  L. Glantz,et al.  Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia. Regional and diagnostic specificity. , 1997, Archives of general psychiatry.

[51]  Jeffrey A Lieberman,et al.  Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity , 1997, Neuropsychopharmacology.

[52]  D. Weinberger,et al.  Cognitive function in schizophrenia , 1997, International clinical psychopharmacology.

[53]  Paul J. Harrison,et al.  Size, shape, and orientation of neurons in the left and right hippocampus: investigation of normal asymmetries and alterations in schizophrenia. , 1997, The American journal of psychiatry.

[54]  D. Lewis,et al.  Development of the Prefrontal Cortex during Adolescence: Insights into Vulnerable Neural Circuits in Schizophrenia , 1997, Neuropsychopharmacology.

[55]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Iyo,et al.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET , 1997, Nature.

[57]  P. Jones.  The early origins of schizophrenia. , 1997, British medical bulletin.

[58]  J. Lieberman,et al.  The evaluation and treatment of first-episode psychosis. , 1997, Schizophrenia bulletin.

[59]  P. Goldman-Rakic,et al.  Functional and anatomical aspects of prefrontal pathology in schizophrenia. , 1997, Schizophrenia bulletin.

[60]  J. Hietala,et al.  Dopamine in schizophrenia. , 1996, Annals of medicine.

[61]  N. Perrone-Bizzozero,et al.  Levels of the growth-associated protein GAP-43 are selectively increased in association cortices in schizophrenia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J C Rajapakse,et al.  Brain anatomic magnetic resonance imaging in childhood-onset schizophrenia. , 1996, Archives of general psychiatry.

[64]  S. Taylor,et al.  Cerebral blood flow activation and functional lesions in schizophrenia , 1996, Schizophrenia Research.

[65]  Streichenwein Sm,et al.  Am J Psychiatry , 1996 .

[66]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[67]  J. Lieberman,et al.  Psychobiologic Correlates of Treatment Response in Schizophrenia , 1996, Neuropsychopharmacology.

[68]  R. Mark Wightman,et al.  Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter , 1996, Nature.

[69]  M S Buchsbaum,et al.  PET and MRI of the thalamus in never-medicated patients with schizophrenia. , 1996, The American journal of psychiatry.

[70]  T. McGlashan,et al.  Early detection and intervention in schizophrenia: research. , 1996, Schizophrenia bulletin.

[71]  A. Yung,et al.  The prodromal phase of first-episode psychosis: past and current conceptualizations. , 1996, Schizophrenia bulletin.

[72]  J. Olney,et al.  Glutamate receptor dysfunction and schizophrenia. , 1995, Archives of general psychiatry.

[73]  Daniel R. Weinberger,et al.  Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground , 1995, Schizophrenia Research.

[74]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[75]  J. Lieberman,et al.  Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. , 1995, The American journal of psychiatry.

[76]  J. Trojanowski,et al.  Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. , 1995, The American journal of psychiatry.

[77]  E. G. Jones,et al.  Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. , 1995, Archives of general psychiatry.

[78]  J. Ehrhardt,et al.  Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. , 1994, Science.

[79]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[80]  Chantal Couture,et al.  Mechanisms of action , 1994, Schizophrenia Research.

[81]  P. Goldman-Rakic.  Working memory dysfunction in schizophrenia. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[82]  Philip D. Harvey,et al.  Cognitive deficits in schizophrenia. , 1993, The Psychiatric clinics of North America.

[83]  J. Lieberman,et al.  Time course and biologic correlates of treatment response in first-episode schizophrenia. , 1993, Archives of general psychiatry.

[84]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[85]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[86]  F. Vogel,et al.  Schizophrenia genesis: The origins of madness , 1991 .

[87]  B. Bunney,et al.  Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia , 1991, Schizophrenia Research.

[88]  F. Benes,et al.  Reduced neuronal size in posterior hippocampus of schizophrenic patients. , 1991, Schizophrenia bulletin.

[89]  B. Pakkenberg,et al.  Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. , 1990, Archives of general psychiatry.

[90]  E. Walker,et al.  Prediction of adult-onset schizophrenia from childhood home movies of the patients. , 1990, The American journal of psychiatry.

[91]  S. Stone-Elander,et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.

[92]  S. Hendry,et al.  Activity-dependent regulation of GABA expression in the visual cortex of adult monkeys , 1988, Neuron.

[93]  A Carlsson,et al.  The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[94]  M. Casanova,et al.  Is there a neuropathology of schizophrenia? , 1988, Biological Psychiatry.

[95]  G. Pearlson,et al.  Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. , 1986, Science.

[96]  D. Weinberger,et al.  Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. , 1986, Archives of general psychiatry.